BusinessNovavax Initiates Phase 1/2 Trial of NanoFlu™ Vaccine in Older AdultsBy Nasdaq OMXSep 19, 2017, 1:05 PM UTC
BusinessCytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart FailureBy Nasdaq OMXSep 19, 2017, 11:30 AM UTC
BusinessMadrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial HypercholesterolemiaBy Nasdaq OMXSep 19, 2017, 11:30 AM UTC
BusinessProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific ConferencesBy Nasdaq OMXSep 19, 2017, 11:01 AM UTC
BusinessAkari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceBy Nasdaq OMXSep 19, 2017, 11:00 AM UTC
BusinessCidara Therapeutics to Present at Two Upcoming ConferencesBy Nasdaq OMXSep 18, 2017, 8:05 PM UTC
BusinessSENS Research Foundation Announces New Research Program on Developing Monoclonal Antibodies Against Glucosepane With David Spiegel LabBy Nasdaq OMXSep 18, 2017, 3:00 PM UTC
BusinessCytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific MeetingBy Nasdaq OMXSep 18, 2017, 11:30 AM UTC
